Published in Biol Blood Marrow Transplant on January 01, 2012
Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone Marrow Transplant (2014) 0.85
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia (2008) 2.37
B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov (2006) 2.27
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant (2003) 1.75
New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant (2008) 1.70
Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant (2003) 1.65
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant (2008) 1.60
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.57
Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood (2005) 1.56
Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant (2007) 1.44
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant (2009) 1.40
A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med (2007) 1.39
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood (2007) 1.36
Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant (2008) 1.32
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood (2004) 1.30
Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant (2007) 1.16
Bronchiolitis obliterans following lung transplantation. Eur J Cardiothorac Surg (2006) 1.12
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica (2011) 1.10
B-cell involvement in chronic graft-versus-host disease. Haematologica (2008) 1.02
Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am (2010) 0.94
Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant (2009) 0.93
Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. Int J Hematol (2011) 0.82
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem (2003) 3.51
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica (2008) 2.26
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal (2006) 2.22
Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med (2009) 2.15
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) 1.96
An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.91
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol (2007) 1.76
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant (2007) 1.74
The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol (2013) 1.73
FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med (2014) 1.72
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant (2002) 1.71
Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol (2012) 1.57
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant (2005) 1.55
Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest (2014) 1.54
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol (2004) 1.50
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.42
Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J (2009) 1.41
Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol (2005) 1.40
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant (2007) 1.40
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol (2004) 1.34
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol (2003) 1.33
Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol (2005) 1.33
Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. J Clin Invest (2013) 1.31
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest (2010) 1.27
Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol (2010) 1.23
Pulmonary sarcoidosis. Semin Respir Crit Care Med (2007) 1.19
PGE(2) inhibition of TGF-beta1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol (2007) 1.19
Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2007) 1.18
Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol (2002) 1.13
A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant (2002) 1.11
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer (2006) 1.11
EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J (2010) 1.11
Leptin modulates neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun (2003) 1.06
Coevolution of TH1, TH2, and TH17 responses during repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect Immun (2010) 1.05
Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med (2015) 1.04
Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. Exp Cell Res (2010) 1.03
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood (2006) 1.02
Usual interstitial pneumonia. Semin Respir Crit Care Med (2006) 1.02
Colonic graft-versus-host disease. Curr Opin Gastroenterol (2005) 1.02
Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol (2011) 0.99
Activation of phosphatase and tensin homolog on chromosome 10 mediates the inhibition of FcgammaR phagocytosis by prostaglandin E2 in alveolar macrophages. J Immunol (2007) 0.98
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol (2012) 0.98
Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10. Infect Immun (2011) 0.96
Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. Infect Immun (2012) 0.95
Blue journal conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med (2015) 0.94
Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.94
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol (2010) 0.93
X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis. Am J Respir Cell Mol Biol (2013) 0.92
PTEN directly activates the actin depolymerization factor cofilin-1 during PGE2-mediated inhibition of phagocytosis of fungi. Sci Signal (2012) 0.92
The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. J Gastroenterol (2009) 0.91
Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res (2014) 0.90
Phosphatase and tensin homologue on chromosome 10 (PTEN) directs prostaglandin E2-mediated fibroblast responses via regulation of E prostanoid 2 receptor expression. J Biol Chem (2009) 0.89
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood (2004) 0.89
Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med (2008) 0.88
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood (2007) 0.87
Tissue inhibitor of matrix-metalloprotease-1 predicts risk of hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis (2011) 0.87
PTEN limits alveolar macrophage function against Pseudomonas aeruginosa after bone marrow transplantation. Am J Respir Cell Mol Biol (2011) 0.84
Maternal infection with Schistosoma japonicum induces a profibrotic response in neonates. Infect Immun (2013) 0.84
Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol (2006) 0.84
Schistosoma japonicum soluble egg antigens attenuate invasion in a first trimester human placental trophoblast model. PLoS Negl Trop Dis (2013) 0.84
Pneumocystis pneumonia increases the susceptibility of mice to sublethal hyperoxia. Infect Immun (2003) 0.80
An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. Am J Respir Crit Care Med (2016) 0.79
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant (2003) 0.78
An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol (2017) 0.77
Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol (2014) 0.77
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma (2011) 0.77
Bilateral marginal keratitis associated with engraftment syndrome after hematopoietic stem cell transplantation. Cornea (2007) 0.77
Tacrolimus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol (2009) 0.76
Innate pathways shape sarcoidosis signaling: from bugs to drugs. Am J Respir Crit Care Med (2011) 0.75
Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 0.75
Infliximab in sarcoidosis: more answers or more questions? Am J Respir Crit Care Med (2006) 0.75
Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab. Leuk Lymphoma (2003) 0.75
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci Rep (2017) 0.75
Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. Am J Epidemiol (2017) 0.75
The graft-versus-leukemia effect in leukemia cutis. Transplantation (2003) 0.75
Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant (2006) 0.75